Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study

• Authors: Bożena Sikora-Kupis

Abstracts

EN

A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.

Keywords

EN

non-metastatic castration-resistant prostate cancer; nmCRPC; androgen receptor targeted agents; ARTA; apalutamide; darolutamide; enzalutamide

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2023
• Volume: 13
• Issue: 1
• Pages: 6-8

Dates

published

2023

Contributors

author

Bożena Sikora-Kupis

• Department of Urogenital Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

References

• YamadaY, Beltran H.The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021; 519: 20-9. http://doi.org/10.1016/j.canlet.2021.06.010.
• Cattrini C, Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. Cancers (Basel). 2022; 14(7): 1792.
• Mateo J, Fizazi K, Gillessen S et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019; 75(2): 285-93.
• Roumiguié M, Paoletti X, Neuzillet Y et al. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncol. 2021; 17(14): 1811-23.
• Mori K, Mostafaei H, Pradere B et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020; 25: 1892-900.

Identifiers

DOI

10.24292/01.OR.131319323

Biblioteka Nauki

22676707